Competitive Endogenous RNA Network Construction and Comparison of Lung Squamous Cell Carcinoma in Smokers and Nonsmokers

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2019 Dec 31

PMID 31885738

Citations 9

Authors

Yan Yao

Tingting Zhang

Lingyu Qi

Ruijuan Liu

Gongxi Liu

Xue Wang

Jie Li

Jia Li

Changgang Sun

Affiliations

Soon will be listed here.

Abstract

Background: Lung squamous cell carcinoma (LUSC) is a subtype of highly malignant lung cancer with poor prognosis, for which smoking is the main risk factor. However, the underlying genetic and molecular mechanisms of smoking-related LUSC remain largely unknown.

Methods: We mined existing LUSC-related mRNA, miRNA, and lncRNA transcriptome data and corresponding clinical data from The Cancer Genome Atlas (TCGA) database and divided them into smoking and nonsmoking groups, followed by differential expression analysis. Functional enrichment analysis of the unique differentially expressed mRNAs of the two groups was performed using the DAVID database. Subsequently, the lncRNA-miRNA-mRNA competing endogenous RNA (ceRNA) network of LUSC in smoking and nonsmoking groups was constructed. Finally, survival analyses were performed to determine the effects of differentially expressed lncRNAs/mRNAs/miRNAs that were involved in the ceRNA network on overall survival and to discover the hub genes.

Results: A total of 1696 lncRNAs, 125 miRNAs, and 3246 mRNAs and 1784 lncRNAs, 96 miRNAs, and 3229 mRNAs with differentially expressed profiles were identified in the smoking and nonsmoking groups, respectively. The ceRNA network and survival analysis revealed four lncRNAs (LINC00466, DLX6-AS1, LINC00261, and AGBL1), one miRNA (hsa-mir-210), and two mRNAs (CITED2 and ENPP4), with the potential as biomarkers for smoking-related LUSC diagnosis and prognosis.

Conclusion: Taken together, our research has identified the differences in the ceRNA regulatory networks between smoking and nonsmoking LUSC, which could lay the foundation for future clinical research.

Citing Articles

LncRNA LINC00466 Promotes the Progression of Breast Cancer miR-4731-5p/EPHA2 Pathway.

Han X, Shi F, Guo S, Li Y, Wang H, Song C Curr Pharm Biotechnol. 2024; 26(1):120-131.

PMID: 38726776 DOI: 10.2174/0113892010290582240419051056.

Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.

Sasa G, Xuan C, Chen M, Jiang Z, Ding X Transl Cancer Res. 2022; 10(12):5406-5429.

PMID: 35116387 PMC: 8799054. DOI: 10.21037/tcr-21-1607.

Comprehensive analysis of the LncRNAs, MiRNAs, and MRNAs acting within the competing endogenous RNA network of LGG.

Ding Y, Liu H, Zhang C, Bao Z, Yu S Genetica. 2022; 150(1):41-50.

PMID: 34993720 DOI: 10.1007/s10709-021-00145-3.

Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients.

Zhang D, Li Y, Yang S, Wang M, Yao J, Zheng Y Cancer Med. 2021; 10(22):8222-8237.

PMID: 34609082 PMC: 8607265. DOI: 10.1002/cam4.4317.

The Genetic and Epigenetic Mechanisms Involved in Irreversible Pulp Neural Inflammation.

Xi X, Ma Y, Xu Y, Ogbuehi A, Liu X, Deng Y Dis Markers. 2021; 2021:8831948.

PMID: 33777260 PMC: 7968449. DOI: 10.1155/2021/8831948.

References

Lee D, Han J, Kim H, Lee J . Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer. 2006; 53(3):339-45. DOI: 10.1016/j.lungcan.2006.05.015. View

Tay Y, Kats L, Salmena L, Weiss D, Tan S, Ala U . Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011; 147(2):344-57. PMC: 3235920. DOI: 10.1016/j.cell.2011.09.029. View

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

Li J, Li P, Zhao W, Yang R, Chen S, Bai Y . Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma. Cancer Cell Int. 2015; 15:48. PMC: 4458341. DOI: 10.1186/s12935-015-0201-5. View

Caley D, Pink R, Trujillano D, Carter D . Long noncoding RNAs, chromatin, and development. ScientificWorldJournal. 2010; 10:90-102. PMC: 5763804. DOI: 10.1100/tsw.2010.7. View

Chen W, Wang J, Liu S, Wang S, Cheng Y, Zhou W . MicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC. J Exp Clin Cancer Res. 2016; 35:76. PMC: 4863317. DOI: 10.1186/s13046-016-0357-4. View

Wong N, Wang X . miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2014; 43(Database issue):D146-52. PMC: 4383922. DOI: 10.1093/nar/gku1104. View

Hua J, Ahmed M, Guo H, Zhang Y, Chen S, Soares F . Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell. 2018; 174(3):564-575.e18. DOI: 10.1016/j.cell.2018.06.014. View

Daniels M, Goh F, Wright C, Sriram K, Relan V, Clarke B . Whole genome sequencing for lung cancer. J Thorac Dis. 2012; 4(2):155-63. PMC: 3378223. DOI: 10.3978/j.issn.2072-1439.2012.02.01. View

10.

Sarver A, French A, Borralho P, Thayanithy V, Oberg A, Silverstein K . Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 2009; 9:401. PMC: 2787532. DOI: 10.1186/1471-2407-9-401. View

11.

Gazdar A . Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28 Suppl 1:S24-31. PMC: 2849651. DOI: 10.1038/onc.2009.198. View

12.

Kong Y, Liang X, Liu L, Zhang D, Wan C, Gan Z . High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model. PLoS One. 2015; 10(9):e0137432. PMC: 4567341. DOI: 10.1371/journal.pone.0137432. View

13.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M . A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011; 147(2):358-69. PMC: 3234495. DOI: 10.1016/j.cell.2011.09.028. View

14.

Zhang S, Zhornitsky S, Angarita G, Li C . Hypothalamic response to cocaine cues and cocaine addiction severity. Addict Biol. 2018; 25(1):e12682. PMC: 6453736. DOI: 10.1111/adb.12682. View

15.

Jeggari A, Marks D, Larsson E . miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 2012; 28(15):2062-3. PMC: 3400968. DOI: 10.1093/bioinformatics/bts344. View

16.

Markou A, Sourvinou I, Vorkas P, Yousef G, Lianidou E . Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013; 81(3):388-396. DOI: 10.1016/j.lungcan.2013.05.007. View

17.

Chou C, Shrestha S, Yang C, Chang N, Lin Y, Liao K . miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2017; 46(D1):D296-D302. PMC: 5753222. DOI: 10.1093/nar/gkx1067. View

18.

Li F, Huang C, Li Q, Wu X . Construction and Comprehensive Analysis for Dysregulated Long Non-Coding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network in Gastric Cancer. Med Sci Monit. 2018; 24:37-49. PMC: 5761711. DOI: 10.12659/msm.905410. View

19.

Perez-Moreno P, Brambilla E, Thomas R, Soria J . Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012; 18(9):2443-51. DOI: 10.1158/1078-0432.CCR-11-2370. View

20.

Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H . Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer. Clin Cancer Res. 2018; 25(6):1817-1827. DOI: 10.1158/1078-0432.CCR-18-1414. View